Limitations and use of PSA derivatives in the screening and risk stratification of prostate cancer

Urol Oncol. Nov-Dec 2009;27(6):583-4. doi: 10.1016/j.urolonc.2009.06.011.
No abstract available

Publication types

  • News

MeSH terms

  • Diagnostic Errors*
  • Disease Progression
  • False Positive Reactions
  • Humans
  • Male
  • Mass Screening*
  • Predictive Value of Tests
  • Prostate-Specific Antigen / blood*
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / diagnosis*
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Sentinel Surveillance

Substances

  • Prostate-Specific Antigen